Related references
Note: Only part of the references are listed.Metabolism of MRX-I, a Novel Antibacterial Oxazolidinone, in Humans: The Oxidative Ring Opening of 2,3-Dihydropyridin-4-One Catalyzed by Non-P450 Enzymes
Jian Meng et al.
DRUG METABOLISM AND DISPOSITION (2015)
Biotransformation and bioactivation reactions of alicyclic amines in drug molecules
Jayaprakasam Bolleddula et al.
DRUG METABOLISM REVIEWS (2014)
Identification of Metabolites of N-(5-Benzoyl-2-(4-(2-Methoxyphenyl)piperazin-1-yl)thiazol-4-yl)pivalamide Including CYP3A4-Mediated C-Demethylation in Human Liver Microsomes with High-Resolution/High-Accuracy Tandem Masss
Min Song et al.
DRUG METABOLISM AND DISPOSITION (2014)
The Metabolic Drug-Drug Interaction Profile of Dabrafenib: In Vitro Investigations and Quantitative Extrapolation of the P450-Mediated DDI Risk
Sarah K. Lawrence et al.
DRUG METABOLISM AND DISPOSITION (2014)
Pharmacokinetics, Metabolism, and Excretion of [14C]Axitinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Humans
Bill J. Smith et al.
DRUG METABOLISM AND DISPOSITION (2014)
Carbon-Carbon Bond Cleavage in Activation of the Prodrug Nabumetone
Fatbardha Varfaj et al.
DRUG METABOLISM AND DISPOSITION (2014)
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans
Martin E. Dowty et al.
DRUG METABOLISM AND DISPOSITION (2014)
Axitinib for the Management of Metastatic Renal Cell Carcinoma
Bernard Escudier et al.
Drugs in research & development (2013)
Metabolism and Disposition of Vilanterol, a Long-Acting beta(2)-Adrenoceptor Agonist for Inhalation Use in Humans
Andrew W. Harrell et al.
DRUG METABOLISM AND DISPOSITION (2013)
Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation
David A. Bershas et al.
DRUG METABOLISM AND DISPOSITION (2013)
Idiosyncratic Adverse Drug Reactions: Current Concepts
Jack Uetrecht et al.
PHARMACOLOGICAL REVIEWS (2013)
Metabolic map and bioactivation of the anti-tumour drug noscapine
Zhong-Ze Fang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Metabolism and Pharmacokinetics of Indacaterol in Humans
Mark Kagan et al.
DRUG METABOLISM AND DISPOSITION (2012)
Unusual Glucuronides
Upendra A. Argikar
DRUG METABOLISM AND DISPOSITION (2012)
Pharmacology and Therapeutics of Bronchodilators
Mario Cazzola et al.
PHARMACOLOGICAL REVIEWS (2012)
Rearrangement reactions catalyzed by cytochrome P450s
Paul R. Ortiz de Montellano et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2011)
Unusual P450 reactions in plant secondary metabolism
Masaharu Mizutani et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2011)
Comparison of In Vitro Metabolism of Ticlopidine by Human Cytochrome P450 2B6 and Rabbit Cytochrome P450 2B4
Jyothi C. Talakad et al.
DRUG METABOLISM AND DISPOSITION (2011)
A Baeyer-Villiger Oxidation Specifically Catalyzed by Human Flavin-Containing Monooxygenase 5
W. George Lai et al.
DRUG METABOLISM AND DISPOSITION (2011)
Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite
Anthony G. Borel et al.
DRUG METABOLISM AND DISPOSITION (2011)
Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system
Håkan Askmark et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Update Information on Drug Metabolism Systems— 2009, Part I
F. Peter Guengerich et al.
CURRENT DRUG METABOLISM (2010)
Identification of Two Novel Metabolites of SCH 486757, a Nociceptin/Orphanin FQ Peptide Receptor Agonist, in Humans
Natalia A. Penner et al.
DRUG METABOLISM AND DISPOSITION (2010)
The Efficacy of a NOP1 Agonist (SCH486757) in Subacute Cough
Ashley Woodcock et al.
LUNG (2010)
Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
Handan He et al.
DRUG METABOLISM AND DISPOSITION (2009)
Metabolism of Ticlopidine in Rats: Identification of the Main Biliary Metabolite as a Glutathione Conjugate of Ticlopidine S-Oxide
Shinji Shimizu et al.
DRUG METABOLISM AND DISPOSITION (2009)
A Predominate Role of CYP1A2 for the Metabolism of Nabumetone to the Active Metabolite, 6-Methoxy-2-naphthylacetic Acid, in Human Liver Microsomes
Miia Turpeinen et al.
DRUG METABOLISM AND DISPOSITION (2009)
The Anti-Cancer Activity of Noscapine: A Review
Massoud Mahmoudian et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2009)
Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice:: Characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance
Chandra Prakash et al.
DRUG METABOLISM AND DISPOSITION (2008)
Pharmacokinetics, Metabolism, and Excretion of Torcetrapib, a Cholesteryl Ester Transfer Protein Inhibitor, in Humans
Deepak Dalvie et al.
DRUG METABOLISM AND DISPOSITION (2008)
Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin
Wei Lu et al.
DRUG METABOLISM AND DISPOSITION (2008)
Enzymatic C-demethylation of 1-[2-(5-tert-butyl-[1,3,4]oxadiazole-2-carbonyl)-4-fluoro-pyrrolidin-1-yl]-2-(2-hydroxy-1,1-dimethyl-ethylamino)ethanone(LC15-0133) in rat liver microsomes
Hye Hyun Yoo et al.
DRUG METABOLISM AND DISPOSITION (2008)
The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond
G. Panina
DIABETES OBESITY & METABOLISM (2007)
In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug
Esther F. A. Brandon et al.
INVESTIGATIONAL NEW DRUGS (2007)
Mechanisms of cytochrome p450 substrate oxidation: MiniReview
F. Peter Guengerich
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2007)
Sulfinpyrazone C-glucuronidation is catalyzed selectively by human UDP-glucuronosyltransferase 1A9
Oranun Kerdpin et al.
DRUG METABOLISM AND DISPOSITION (2006)
Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone
Takahito Nishiyama et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2006)
Selective metabolism of vincristine in vitro by CYP3A5
Jennifer B. Dennison et al.
DRUG METABOLISM AND DISPOSITION (2006)
In vitro metabolic activation of thiabendazole via 5-hydroxythiabendazole: Identification of a glutathione conjugate of 5-hydroxythiabendazole
D Dalvie et al.
DRUG METABOLISM AND DISPOSITION (2006)
Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily
PI Mackenzie et al.
PHARMACOGENETICS AND GENOMICS (2005)
Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir
L Doyon et al.
ANTIVIRAL RESEARCH (2005)
In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: Formation of reactive iminium and quinone type metabolites
ZP Zhang et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2005)
Platelet ADP receptor antagonists: ticlopidine and clopidogrel
AK Jacobson
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2004)
Nabumetone - Therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis
T Hedner et al.
DRUGS (2004)
Conversion of the 2,2,6,6-tetramethylpiperidine moiety to a 2,2-dimethylpyrrolidine by cytochrome P450: Evidence for a mechanism involving nitroxide radicals and heme iron
WJ Yin et al.
BIOCHEMISTRY (2004)
An EP2 receptor-selective prostaglandin E2 agonist induces bone healing
VM Paralkar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A novel P450-catalyzed transformation of the 2,2,6,6-tetramethyl piperidine moiety to a 2,2-dimethyl pyrrolidine in human liver microsomes:: Characterization by high resolution quadrupole-time-of-flight mass spectrometry and 1H-NMR
WJ Yin et al.
DRUG METABOLISM AND DISPOSITION (2003)
A preliminary report on the application of noscapine in the treatment of stroke
M Mahmoudian et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Metabolism of (S)-5,6-difluoro-4-cyclopropylethynyl-4-trifluoromethyl-3, 4-dihydro-2(1H)-quinazolinone, a non-nucleoside reverse transcriptase inhibitor, in human liver microsomes. Metabolic activation and enzyme kinetics
H Chen et al.
DRUG METABOLISM AND DISPOSITION (2003)
Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2-and 3-hydroxylated metabolites
RE Pearce et al.
DRUG METABOLISM AND DISPOSITION (2002)
Delineating novel metabolic pathways of DPC 963, a non-nucleoside reverse transcriptase inhibitor, in rats. characterization of glutathione conjugates of postulated oxirene and benzoquinone imine intermediates by LC/MS and LC/NMR
H Chen et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2002)
Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P4502C19
NT Ha-Duong et al.
BIOCHEMISTRY (2001)
Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity
FP Guengerich
CHEMICAL RESEARCH IN TOXICOLOGY (2001)
Multiple oxidants in cytochrome P450 catalyzed reactions: Implications for drug metabolism
ADN Vaz
CURRENT DRUG METABOLISM (2001)
Evidence for cytochrome P4501A2-mediated protein covalent binding of thiabendazole and for its passive intestinal transport:: use of human and rabbit derived cells
C Eeckhoutte et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2000)
An analysis of the possibility for health implications of joint actions and interactions between food additives
JP Groten et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2000)
Share Paper
